Drug reaction with eosinophilia and systemic symptoms in patients hospitalized with COVID-19: a case series from a large US healthcare system
Br J Dermatol
.
2022 Oct;187(4):619-622.
doi: 10.1111/bjd.21706.
Epub 2022 Jul 12.
Authors
Bethany Cucka
1
,
Bianca Biglione
1
,
Li Zhou
2
3
,
Elizabeth J Phillips
4
,
Fatima Bassir
2
,
Upeka Samarakoon
5
,
Renajd Rrapi
1
,
Sidharth Chand
1
,
Liqin Wang
2
3
,
Santiago Alvarez-Arango
6
7
,
Kimberly G Blumenthal
5
,
Daniela Kroshinsky
1
Affiliations
1
Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.
2
Division of General Internal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
3
Harvard Medical School, Boston, MA, USA.
4
Center for Drug Safety and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
5
Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
6
Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
7
Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
PMID:
35700153
PMCID:
PMC9350236
DOI:
10.1111/bjd.21706
No abstract available
Publication types
Letter
MeSH terms
COVID-19*
Delivery of Health Care
Drug Hypersensitivity Syndrome* / diagnosis
Drug Hypersensitivity Syndrome* / etiology
Eosinophilia* / chemically induced
Humans
Grants and funding
R01 AI150295/AI/NIAID NIH HHS/United States
T32 GM066691/GM/NIGMS NIH HHS/United States